Conditions
Essential Thrombocythemia
Trial Purpose
This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythaemia (ET) who have an inadequate response to or are intolerant of hydroxyurea.
The primary study hypothesis is that bomedemstat is superior to the best available therapy with respect to durable clinical–haematological response (DCHR).
NATIONAL TRIAL REFERENCE NUMBER
NCT06079879
EU CT
2023-504865-21
When speaking to your doctor or clinical trial representative, please have the trial reference number available.
Resources
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Age Range
18+
Sex
All
About The Trial
All patients who enroll in the trial will receive the investigational medication or a best available treatment while on the study.
50% will receive bomedemstat
50% will receive the best available treatment (anagrelide, busulfan, interferon, or ruxolitinib). The trial doctor will tell you which drug you will get if you are put in Group 2.
*A computer will decide which group you are put in. You have an equal chance of being placed in either group.
Trial Phase
Trial Phase 3
Tests the medicine or vaccine in large groups of trial participants (from several hundred to several thousand). For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics or doctors’ offices.
Trial start and end dates
- Actual study start date 31 December 2023
- Estimated primary completion date 18 August 2026
- Estimated study completion date 18 August 2028
Trial locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.
What can you do next?
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.
Taking part in a clinical trial is an important decision
If you are considering joining a clinical trial, first learn as much as you can about:
- The investigational treatment that is being studied
- What the risks and possible benefits are for participants
Talk to your doctor about the clinical trial before you decide to join.
Read our “What to Consider” page for more questions to ask and think about